These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19262071)

  • 21. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
    Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
    Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic study of copper (II) acetylsalicylate.
    Iqbal MS; Sher M; Pervez H; Saeed M
    Biol Trace Elem Res; 2008 Sep; 124(3):283-8. PubMed ID: 18478192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of Pharmacokinetic Interaction between Aspirin and Warfarin.
    Fiske WD; Connell JM; Benedek IH
    Am J Ther; 1995 Jun; 2(6):407-413. PubMed ID: 11850685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate].
    Sun YP; Tan L; Wang Y; Song JH
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(29):2033-5. PubMed ID: 17925173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.
    Chung JY; Cho JY; Yu KS; Kim JR; Lim KS; Sohn DR; Shin SG; Jang IJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):595-600. PubMed ID: 17687269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin.
    Jalil NJ; Bannur Z; Derahman A; Maskon O; Darinah N; Hamidi H; Gunasekaran OA; Rafizi M; Azreen NI; Kek TL; Salleh MZ
    J Pharm Pharm Sci; 2015; 18(3):474-83. PubMed ID: 26517138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The human UDP-glucuronosyltransferase: identification of key residues within the nucleotide-sugar binding site.
    Patana AS; Kurkela M; Goldman A; Finel M
    Mol Pharmacol; 2007 Sep; 72(3):604-11. PubMed ID: 17578897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of salicylic acid levels in normal subjects after rectal versus oral dosing.
    Maalouf R; Mosley M; James Kallail K; Kramer KM; Kumar G
    Acad Emerg Med; 2009 Feb; 16(2):157-61. PubMed ID: 19076101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.
    Limenta LM; Jirasomprasert T; Tankanitlert J; Svasti S; Wilairat P; Chantharaksri U; Fucharoen S; Morales NP
    Br J Clin Pharmacol; 2008 Jun; 65(6):908-16. PubMed ID: 18318774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative determination of five metabolites of aspirin by UHPLC-MS/MS coupled with enzymatic reaction and its application to evaluate the effects of aspirin dosage on the metabolic profile.
    Li JP; Guo JM; Shang EX; Zhu ZH; Liu Y; Zhao BC; Zhao J; Tang ZS; Duan JA
    J Pharm Biomed Anal; 2017 May; 138():109-117. PubMed ID: 28192718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria.
    Palikhe NS; Kim SH; Nam YH; Ye YM; Park HS
    Allergy Asthma Immunol Res; 2011 Oct; 3(4):273-6. PubMed ID: 21966608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy.
    Jain P; Shastri S; Gulati S; Kaleekal T; Kabra M; Gupta N; Gupta YK; Pandey RM
    Neurol India; 2015; 63(1):35-9. PubMed ID: 25751467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism of aspirin after therapeutic and toxic doses.
    Patel DK; Hesse A; Ogunbona A; Notarianni LJ; Bennett PN
    Hum Exp Toxicol; 1990 May; 9(3):131-6. PubMed ID: 2375880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets.
    Montgomery PR; Sitar DS
    Biopharm Drug Dispos; 1986; 7(1):21-5. PubMed ID: 3955197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE.
    Tankanitlert J; Morales NP; Howard TA; Fucharoen P; Ware RE; Fucharoen S; Chantharaksri U
    Pharmacology; 2007; 79(2):97-103. PubMed ID: 17164591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses.
    Buntenkötter K; Osmers M; Schenk I; Schänzer W; Machnik M; Düe M; Kietzmann M
    BMC Vet Res; 2017 Jan; 13(1):28. PubMed ID: 28103874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum.
    Lee S; Johnson D; Klein J; Eppler J
    Vet Hum Toxicol; 1995 Jun; 37(3):224-5. PubMed ID: 7571349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites.
    Ho PC; Triggs EJ; Bourne DW; Heazlewood VJ
    Br J Clin Pharmacol; 1985 May; 19(5):675-84. PubMed ID: 4005105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro enantioselective displacement of propranolol from protein binding sites by acetyl salicylic acid and salicylic acid.
    Rezaei Z; Khabnadideh S; Hemmateenejad B; Dehghani Z
    Int J Pharm; 2007 Sep; 342(1-2):78-81. PubMed ID: 17590545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic pilot study with imidazole 2-hydroxybenzoate using new analytical methods.
    Kuemmerle HP; Hitzenberger G; Nieder G; Rasper J; Jaeger H
    Int J Clin Pharmacol Ther Toxicol; 1984 Oct; 22(10):521-9. PubMed ID: 6334657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.